Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 291
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | ||
| NCT03625466 | A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | ||
| NCT07437105 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | ||
| NCT06226454 | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993 | ||
| NCT05668741 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | ||
| NCT01275599 | Drug-Drug Interaction Study Between Telaprevir and Buprenorphine | ||
| NCT01060566 | Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 | ||
| NCT00262483 | Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C | ||
| NCT03912233 | A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis | ||
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | ||
| NCT05851157 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548 | ||
| NCT06299696 | A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists | ||
| NCT05553366 | Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | ||
| NCT01726946 | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | ||
| NCT04362761 | A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy | ||
| NCT05951205 | Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype | ||
| NCT04702360 | ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation | ||
| NCT06529796 | Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment | ||
| NCT05867147 | An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants | ||
| NCT05866055 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults | ||
| NCT02797132 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | ||
| NCT01590459 | 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate | ||
| NCT03304522 | A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy | ||
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy | ||
| NCT07010406 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations | ||
| NCT07654296 | Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | ||
| NCT05076149 | A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation | ||
| NCT04235140 | Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation | ||
| NCT00389298 | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. | ||
| NCT04969224 | A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) | ||
| NCT02347657 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor | ||
| NCT05153317 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older | ||
| NCT01897233 | Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT02730208 | A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | ||
| NCT03150719 | A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) | ||
| NCT03068312 | A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation | ||
| NCT04105972 | A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del | ||
| NCT02565914 | A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation | ||
| NCT03525574 | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | ||
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | ||
| NCT05324410 | A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants | ||
| NCT04977336 | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | ||
| NCT00205465 | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 | ||
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | ||
| NCT04058210 | VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes) | ||
| NCT05635110 | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants | ||
| NCT05535959 | A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor | ||
| NCT00457821 | Safety Study of Ivacaftor in Subjects With Cystic Fibrosis | ||
| NCT07700225 | Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension | ||
| NCT03224351 | A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis |
